Drug metabolism and pharmacokinetics in support of drug design

Current Pharmaceutical Design

Volumn 15, Issue 19, 2009, Pages 2170-2183

  Tang, Wei ^a   Lu, Anthony Y H ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Drug discovery; Drug metabolism; Pharmacokinetics; Structure activity relationship

Indexed keywords

CELECOXIB; CLARITHROMYCIN; EPEREZOLID; ERYTHROMYCIN; KETOCONAZOLE; LINEZOLID; MACROLIDE; MELANOCORTIN RECEPTOR AGONIST; MONTELUKAST; MRK 10; MRK 11; MRK 12; MRK 13; MRK 14; MRK 15; MRK 16; MRK 17; MRK 2; MRK 4; MRK 5; MRK 6; MRK 7; MRK 8; MRK 9; NICOTINIC ACID; RALOXIFENE; ROSIGLITAZONE; SINGLAIR; SITAGLIPTIN; TERFENADINE; TREPDATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HEART VENTRICLE ARRHYTHMIA; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PAIN; PHARMACEUTICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; STAPHYLOCOCCAL PNEUMONIA; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69249108563     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682451     Document Type: Review

References (92)

1. Marshall Jr, EK. The present status and problems of bacterial chemotherapy. Science 1940; 91: 345-50.
2. Newell HW, Lidz T. The toxicity of atabrine to the central nervous system. Am J Psychiatry 1946; 102: 805-18.
3. Shannon JA, Earle DP, Brodie BB, Taggart JV, Berliner RW. The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther 1944; 81: 307-30.
4. Brodie BB, Axelrod J. The fate of acetanilide in man. J Pharmacol Exp Ther 1948; 94: 29-38.
5. Murray T, Goldberg M. Analgesic abuse and renal disease. Ann Rev Med 1975; 26: 537-50.
6. Parkinson A. In: Klaassen CD, Ed. Biotransformation of xenobiotics. Casarett & Doull's Toxicology: The basic science of poisons, 5th ed. Columbus, OH: McGraw-Hill, Inc. 1996; pp. 133-186.
7. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006; 27: 425-46
8. MacCoss M, Baillie TA. Organic chemistry in drug discovery. Science 2004; 303: 1810-3.
9. White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000; 40: 133-57.
10. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev 2004; 3: 711-5.
11. Tang W, Wang RW, Lu AYH. Utility of recombinant cytochrome P450 enzymes: A drug metabolism perspective. Curr Drug Metab 2005; 6: 503-17.
12. Zhang Z, Li Y, Shou M, Zhang Y, Ngui JS, Stearns RA, et al. Influence of different recombinant systems on the cooperativity exhibited by cytochrome P4503A4. Xenobiotica 2004; 34: 473-86.
13. Kumar V, Rock DA, Warren CJ, Tracy TS, Wahistrom JL. Enzyme source effects on CYP2C9 kinetics and inhibition. Drug Metab Dispos 2006; 34: 1903-8.
14. Kern A, Bader A, Pichlmary R, Sewing K-F. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol 1997; 54: 761-72.
15. Brockunier LL, He J, Colwell LF, Habulihaz B, He H, Leiting B, et al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2004; 14: 4763-6.
16. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, et al. (2R)-4-Oxo-4-3-(trifluoromethyl)- 5,6-dihydro1,2,4triazolo4,3- apyrazin-7(8H)-yl-1-(2,4,5- trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005; 48: 141-51.
17. Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, Smet MD, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55-72.
18. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor 14Csitagliptin in humans. Drug Metab Dispos 2007; 35: 533-8.
19. Tang W, Stearns RA, Chen Q, Bleasby K, Teffera Y, Colletti A, et al. Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N-sulfonylated dipeptide VLA-4 antagonist in rats. Xenobiotica 2008; 38: 223-37.
20. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets 2001; 1: 181-99.
21. Paladino JA. Linezolid: An oxazolidinone antimicrobial agent. Am J Health-Syst Pharm 2002; 59: 2413-25.
22. FDA. Guidance for industry, investigators, and reviewers: Exploratory IND studies. http://www.fda.gov/cder/guidance/index.htm 2006.
23. Hsieh Y. HPLC-MS/MS in drug metabolism and pharmacokinetic screening. Expert Opin Drug Metab Toxicol 2008; 4: 93-101.
24. Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, et al. Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series. ChemMedChem 2008; 3: 136-44.
25. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-5-(4-methylphenyl)- 3-(trifluoromethyl)-1H- pyrazol-1-ylbenzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-65.
26. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NWK, Jessen SM, et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 2000; 28: 514-21.
27. Paulson SK, Hribar JD, Liu NWK, Hajdu E, Bible Jr RH, Piergies A, et al. Metabolism and excretion of 14Ccelecoxib in healthy male volunteers. Drug Metab Dispos 2000; 28: 308-14.
28. Karim A, Tolbert D, Burton E, Piergies A, Harper K, Paulson S, et al. A highly selective inhibitor of cyclooxygenase-2: Disposition kinetics in man and identification of its major CYP450 isozyme in its biotransformation. Pharm Res 1997; 14: S617.
29. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. Drug-protein covalent adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 2004; 17: 3-16.
30. Baillie TA. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008; 21: 129-37.
31. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ: Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-76.
32. Williams DP: Toxicophores: Investigations in drug safety. Toxicology 2006; 226: 1-11.
33. Tang W, Miller MR. In: Yan Z, Caldwell GW, Eds. Thiol conjugation in in vitro drug metabolism: Methods in pharmacology and toxicology, Optimization in drug discovery: In vitro Methods. Totowa, NJ: Humana Press Inc. 2004; pp. 369-383.
34. Zhang Z, Chen Q, Li Y, Doss GA, Dean BJ, Ngui JS, et al. In vitro bioactivation of dihydrobenzoxathiin selective estrogen receptor modulators by cytochrome P450 3A4 in human liver microsomes: Formation of reactive iminium and quinone type metabolites. Chem Res Toxicol 2005; 18: 675-85.
35. Tang W. Drug metabolite profiling and elucidation of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2007; 3: 407-20.
36. Kumar S, Kassahun K, Tschirret-Guth RA, Mitra K, Baillie TA. Minimizing metabolic activation during pharmaceutical lead optimization: Progress, knowledge gaps and future directions. Curr Opin Drug Discov Dev 2008; 11: 43-52.
37. Lin JH, Wong BK. Complexities of glucuronidation affecting in vitro-in vivo extrapolation. Curr Drug Metab 2002; 3: 623-46.
38. Hagmann WK. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists. Curr Topics Med Chem 2004; 4: 1461-71.
39. 2 receptor antagonist, (3R)-4-(4-chlorobenzyl -7-fluoro-5- (methylsulfonyl)-1,2,3,4- tetrahydrocyclopentabindol-3-yl-acetic acid. J Med Chem 2007; 50: 794-806.
40. 2 receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 2007; 37: 514-33.
41. Karanam B, Maderia M, Bradley S, Wenning L, Desai R, Soli E, et al. Absorption, metabolism, and excretion of 14CMK-0524, a prostaglandin D2 receptor antagonist, in humans. Drug Metab Dispos 2007; 35: 1196-202.
42. Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, De Hoon JN, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008; 83: 840-7.
43. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and clinical implications. Clin Pharmacokinet 1998; 35: 361-90.
44. Rodrigues AD, Winchell GA, Dobrinska MR. Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: The need for quantitative databases. J Clin Pharmacol 2001; 41: 368-73.
45. Zhang H, Zhang D, Li W, Yao M, D'Arienzo CD, Li Y-X, et al. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. Drug Metab Dispos 2007; 35: 795-805.
46. FDA. Guidance for Industry: Drug interaction studies - Study design, data analysis, and implications for dosing and labeling. http://www.fda.gov/cder/guidance/index.htm 2006.
47. Walsky RL, Obach RS, Gaman EA, Gleeson J-PR, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 2005; 33: 413-8.
48. Friedman E, Ramakrishnan R, Larson P, Korzekwa K, Wagner JA, Migoya E. An open-label, randomized, 2-period, crossover study, to assess the effects of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy adults. Clin Pharmacol Ther 2006; P72.
49. Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, et al. Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 2002; 15: 907-14.
50. Evista® Prescribing information, www.evista.com.
51. Ito K, Ogihara K, Kanamitsu S-I, Itoh T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003; 31: 945-54.
52. Polasek TM, Miners JO. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Pharmacokinet Dispos 2006; 62: 203-8.
53. Oikkola K, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg J-J, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305.
54. Yeates RA, Laufen H, Zimmerman T. Interaction between midazolam and clarithromycin: Comparison with azithromycin. Int J Clin Pharm Ther 1996; 34: 400-5.
55. Tang W, Stearns RA, Wang RW, Miller RR, Chen Q, Ngui J, et al. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: A case study with melanocortin 4 receptor agonists. Xenobiotica 2008; 38: 1437-57.
56. Ward P. Importance of drug transporters in pharmacokinetics and drug safety. Toxicol Mech Method 2008; 18: 1-10.
57. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharmaceut 2006; 3: 62-9.
58. Zhang L, Zhang Y(D), Strong JM, Reynolds KD, Huang S-M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 2008; 38: 709-24.
59. Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005; 77: 503-14.
60. Gao Y-D, Olson SH, Balkovec JM, Zhu Y, ROYO I, Yabut J, et al. Attenuating pregnane X receptor (PXR) activation: A molecular modeling approach. Xenobiotica 2007; 37: 124-38.
61. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CEAC, Keohane CA, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in Mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-7.
62. Sadeque AJM, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231-7.
63. Chrishty M, Reichel A, Siva J, Abbott NJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS-side-effects of modern antihistamines. J Drug Target 2001; 9: 223-8.
64. Doan KMM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp ther 2002; 303: 1029-37.
65. Lin JH. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drug Today 2004; 40: 5-22.
66. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 325: 349-56.
67. Raub TJ. P-Glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharmaceut 2005; 3: 3-25.
68. Salerno M, Przewloka T, Fokt I, Priebe W, Garnier-Suillerot A. Preferential efflux by P-glycoprotein, but not MRP1, of compounds containing a free electron donor amine. Biochem Pharmacol 2002; 63: 1471-9.
69. Cox CD, Breslin MJ, Whitman DB, Coleman PJ, Garbaccio RM, Fraley ME, et al. Kinesin spindle protein (KSP) inhibitor. Part V: Discovery of 2-propyamino-2,4-diary-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein. Bioorg Med Chem Lett 2007; 17: 2697-702.
70. Shen DD, Artru AA, Adkison KK. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacokinetics. Adv Drug Deliv Rev 2004; 56: 1825-57.
71. Lin JH. CSF as a surrogate for assessing CNS exposure: An industrial perspective. Curr Drug Metab 2008; 9: 46-59.
72. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, et al. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Dispos 2003; 31: 1251-4.
73. Mindermann T, Zimmerli W, Gratzl O. Rifampin concentrations in various compartments of the human brain: A novel method for determining drug levels in the cerebral extracellular space. Antimicrob Agents Chemother 1998; 42: 2626-9.
74. Groothuis DR, Ward S, Schlageter KE, Itskovich AC, Schwerin SC, Allen CV, et al. Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res 1998; 803: 218-30.
75. Wan, H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 2007; 50: 4606-15.
76. Felmlee MA, Lon H-K, Gonzalez FJ, Yu A-M. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 2008; 36: 435-41.
77. Gonzalez FJ. CYP3A4 and pregnane X receptor humanized mice. J Biochem Mol Toxicol 2007; 27: 158-62.
78. - mice. Nature Biotech 2007; 25: 903-10.
79. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008; 246: 9-17.
80. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-12.
81. Okumura H, Katoh M, Sawada T, Nakajima M, Soene Y, Yabuuchi H, et al. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 2007; 97: 533-8.
82. Lin JH. Applications and limitations of genetically modified mouse models in drug discovery and development. Curr Drug Metab 2008; 9: 419-38.
83. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007; 8: 839-45.
84. Prestwich GD. Evaluating drug efficacy and toxicology in three dimensions: Using synthetic extracellular matrices in drug discovery. Accounts Chem Res 2008; 41: 139-48.
85. Prestwich GD, Liu Y, Yu B, Shu XZ, Scott A. 3-D Culture in synthetic extracellular matrices: New tissue models for drug toxicology and cancer drug discovery. Advan Enzyme Regul 2007; 47: 196-207.
86. Tian X, Zhang P, Zamek-Gliszczynski MJ, Brouwer KLR. Knocking down transport: Applications of RNA interference in the study of drug transport proteins. Drug Metab Rev 2005; 37: 705-23.
87. Yu A-M. Small interfering RNA in drug metabolism and transport. Curr Drug Metab 2007; 8: 700-8.
88. Kojima K, Nagata K, Matsubara T, Yamazoe Y. Broad but distinct role of pregnane X receptor on the expression of individual cytochrome P450s in human hepatocytes. Drug Metab Pharmacokinet 2007; 22: 276-86.
89. van de Water FH, Boerman OC, Wouterse AC, Peters JGP, Russel FGM, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006; 1393-7.
90. Hancox JC, McPate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008; 119(2): 118-32.
91. Kerns EH. Current drug metabolism. Curr Drug Metab 2008; 9(9): 845-6
92. Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG. Pharmacokinetics in drug discovery. J Pharm Sci 2008; 97(2): 654-90.